Eledon Pharmaceuticals, Inc.
ELDNEledon Pharmaceuticals is a clinical-stage biotechnology company specializing in immunology and the development of therapies targeting the CD40 Ligand (CD40L) pathway.
Table of contents
Earnings
Next report
Aug 13, 2026 (In 2 weeks)Competitors
By market cap
By revenue growth
Profile
Eledon Pharmaceuticals is a clinical-stage biotechnology company specializing in immunology and the development of therapies targeting the CD40 Ligand (CD40L) pathway. The company's core value proposition lies in its lead compound, tegoprubart, which is designed to protect transplanted organs from rejection and treat neurodegenerative diseases by modulating immune cell activation without the toxic side effects of traditional calcineurin inhibitors.
Eledon is a specialized clinical-stage player focused on a well-validated biological target (CD40L) with a second-generation antibody designed to avoid the safety issues of earlier therapies.
Questions, answered.
- What is Eledon Pharmaceuticals, Inc.'s market cap?
- Eledon Pharmaceuticals, Inc. (ELDN) has a market capitalization of $275.6M and trades on NASDAQ.
- Who are Eledon Pharmaceuticals, Inc.'s competitors?
- Eledon Pharmaceuticals, Inc.'s key competitors include Biogen, Insight Molecular Diagnostics Inc. Common Stock, Creative Medical Technology Holdings, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Eledon Pharmaceuticals, Inc. partner with?
- Eledon Pharmaceuticals, Inc.'s notable partners include eGenesis, Inc., University of Chicago Medicine.
- What subsidiaries does Eledon Pharmaceuticals, Inc. have?
- Eledon Pharmaceuticals, Inc.'s subsidiaries include Anelixis Therapeutics, Inc..
- Where is Eledon Pharmaceuticals, Inc. headquartered?
- Eledon Pharmaceuticals, Inc. is headquartered in United States of America and employs approximately 20 people. It has been publicly traded since 2014.